Spermidine, Sleep and Autophagy: Part Two: Three Measurement Problems

Abstract

Part One covered the largest randomised trial of spermidine and cognition, which found nothing. The wider literature does not agree with it, or with itself.

A synthesis published in General Psychiatry in 2025 assembled 22 studies — four interventional trials and eighteen observational — and found associations pointing in both directions, sometimes for the same outcome.

Its most valuable contribution is not the verdict but the diagnosis. Three specific measurement problems explain much of the disagreement, and none of them is about statistics.

1.The Synthesis

Lirong Yu, Bin Li, Lei Feng, Andrea Maier and Brian Kennedy, working across institutions in China, Singapore and the Netherlands, searched the major databases and quality-assessed what they found using the Cochrane risk-of-bias tool, ROBINS-I and the Newcastle-Ottawa Scale.

Their framing is that spermidine is a candidate caloric restriction mimetic — a compound reproducing some physiological effects of eating less without the eating less. Caloric restriction and intermittent fasting raise endogenous spermidine, and spermidine is a recognised natural inducer of autophagy.

Eighteen of the studies were rated good quality on the Newcastle-Ottawa Scale. The authors nonetheless describe small sample sizes and heterogeneity in outcome measures as prevalent, and warrant cautious interpretation.

2.Observational Findings, Pointing Both Ways

Higher spermidine has been associated with reduced risk of cognitive impairment, with larger hippocampal volume and greater cortical thickness, and with better Mini-Mental State Examination scores.

Higher spermidine has also been associated with reduced hippocampal volume, with elevated Alzheimer's disease scores, and with markers of poor sleep quality in older adults.

Those are the same direction of exposure producing opposite directions of outcome, on the same organ, in the same literature. Studies of patients with mild cognitive impairment and Alzheimer's disease similarly split: some report lower spermidine than controls, others higher.

The association with poor sleep deserves flagging on its own, given that Part Four covers a trial measuring sleep architecture after spermidine. It does not predict that trial's outcome. It is a reason not to assume the direction in advance.

3.Problem One: What Is Being Measured

More than 90 per cent of circulating spermidine is bound up in red blood cells. Plasma accounts for approximately 1.2 per cent of whole-blood spermidine.

Two consequences follow. Plasma concentrations are low enough that detection is technically difficult. And minor haemolysis during collection or processing releases spermidine from red cells into the plasma being measured, inflating the reading by an amount that depends on how carefully the sample was handled.

The authors recommend measuring whole blood. Much of the existing literature measured serum or plasma, which means part of the disagreement between studies may be a disagreement between phlebotomy techniques.

4.Problem Two: What Arrives

A pharmacokinetic investigation of high-dose oral spermidine found that blood spermine rose while blood spermidine did not change.

The proposed explanation is conversion during absorption: spermidine is metabolised to spermine in the intestinal wall and the liver, so what reaches the circulation is a downstream molecule. Two studies of long-term adherence to polyamine-rich diets, including traditional Japanese foods such as natto, found the same pattern — altered spermine with no substantial change in blood spermidine.

This is a serious problem for the entire field. If oral spermidine raises spermine rather than spermidine, then attributing any observed benefit to spermidine specifically is unsupported, and the authors say as much.

5.Problem Three: Where It Goes

Under normal physiological conditions, spermidine is generally unable to cross the blood–brain barrier.

It may cross where the barrier is compromised — in animal models under lethal stress, or in patients with traumatic brain injury. This has been proposed to explain a curious observation: people with cognitive impairment sometimes show higher spermidine in both brain and blood than healthy controls, which would follow if impairment involves barrier dysfunction that lets the molecule through.

One reported finding fits that reading uncomfortably well. Participants with mild cognitive impairment who subsequently progressed to Alzheimer's disease had higher plasma spermidine than those whose impairment stayed stable.

The logic here is awkward in both directions, and worth stating plainly. If the barrier is intact, an oral polyamine may not reach the brain at all. If it is permeable enough to admit the molecule, that permeability is itself a feature of the pathology the supplement is meant to prevent.

6.The Four Trials

Set against those three problems, the interventional evidence is thin. Four trials, at doses between 0.9 and 3.3 mg a day.

A 2018 pilot in 28 participants reported moderately enhanced memory, with a confidence interval from −0.01 to 0.35 — an interval containing no effect. SmartAge, covered in Part One, is the twelve-month randomised trial in 100 participants that found nothing. An Austrian trial in 85 older adults with dementia compared wheat germ rolls delivering 3.3 mg against rolls delivering 1.9 mg and reported a 2.23-point MMSE gain in mild dementia, alongside a phonemic fluency change with a p-value of 0.470. A follow-up in 45 people reported a five-point MMSE improvement over twelve months with no control group.

A five-point MMSE gain in dementia patients over a year, in an uncontrolled study, is not a plausible drug effect. It is what an uncontrolled study in a fluctuating condition produces.

The authors' own conclusion is appropriately hedged: spermidine demonstrates potential, and inconsistencies in the evidence require standardised, long-term studies before its role can be established.

Editorial Comment

MindHeaven® uses no spermidine and makes no claim about it. It has no authorised health claim in the European Union.

The reason to read this paper closely is that its three problems are not specific to spermidine. Measuring the wrong compartment, measuring a compound that has been metabolised into something else before it arrives, and assuming a molecule reaches the tissue where the mechanism was described — these recur across the whole supplement literature, and they are usually invisible in the summary a reader encounters.

Part Three turns to what autophagy induction actually does in an animal that receives it, in the one study we found that looked for effects in both directions.